Actively Recruiting

Phase Not Applicable
Age: 40Years - 80Years
All Genders
NCT06602934

Long-term Alterations of Host-microbiome Interactions and Cardiovascular and Respiratory Diseases Progression After Pneumonia

Led by Nantes University Hospital · Updated on 2025-01-17

300

Participants Needed

5

Research Sites

225 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The HOMI-LUNG - HAP study is part of the HOMI-LUNG project, funded by the Horizon Europe program. The "HOMI-LUNG" project is an international, interdisciplinary project that aims to better understand the causal links between respiratory tract infections (i.e. pneumonia) and the progression of cardiovascular disease. More specifically, the project aims to quantify the burden of cardiovascular disease after pneumonia and assess patients\' acceptability of long-term health alterations, as well as to define pneumonia endotypes with distinct pathobiological mechanisms associated with exacerbation of cardiovascular disease.

CONDITIONS

Official Title

Long-term Alterations of Host-microbiome Interactions and Cardiovascular and Respiratory Diseases Progression After Pneumonia

Who Can Participate

Age: 40Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Male or female aged 40 years or older
  • Hospitalized for acute coronary syndrome less than 7 days ago (Group A)
  • Undergoing coronary artery bypass surgery and hospitalized in intensive care unit for more than 12 hours (Group B)
  • Familial high cholesterol or triglycerides with no personal cardiovascular disease and recent negative cardiac exercise test within 12 months (Group C)
  • At least one cardiovascular disease risk factor and recovered from mechanically ventilated hospital-acquired pneumonia during current hospitalization (Group D)
  • Provided informed consent
  • Covered by a health insurance plan
Not Eligible

You will not qualify if you...

  • Older than 80 years
  • Immunosuppression before current hospital stay (including low lymphocyte count, blood cancers, aplasia, recent chemotherapy/radiotherapy, or anti-graft rejection drugs)
  • Pregnant or breastfeeding women
  • Adults under guardianship or trusteeship
  • Low chance of survival at 28 days
  • History of community-acquired or hospital-acquired pneumonia within the last year (Groups A, B, C)

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 5 locations

1

Angers University Hospital

Angers, France

Not Yet Recruiting

2

Nantes University Hospital

Nantes, France

Actively Recruiting

3

Rennes University Hospital

Rennes, France

Not Yet Recruiting

4

Rouen University Hospital

Rouen, France

Not Yet Recruiting

5

Toulouse University Hospital

Toulouse, France

Not Yet Recruiting

Loading map...

Research Team

A

Antoine ROQUILLY

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

SINGLE_GROUP

Primary Purpose

OTHER

Number of Arms

4

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Long-term Alterations of Host-microbiome Interactions and Cardiovascular and Respiratory Diseases Progression After Pneumonia | DecenTrialz